Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577884 | 0.93 | SIGMAR1 (0.47) | SIGMAR1MCHR1CHRM4SLC6A12TMEM97 | |
| SCHEMBL5577373 | 0.91 | SIGMAR1 (0.48) | SIGMAR1MCHR1CHRM4SLC6A12TMEM97 | |
| SCHEMBL5577515 | 0.91 | POLB (0.53) | SIGMAR1MCHR1SLC6A12TMEM97LMNA | |
| SCHEMBL5577451 | 0.89 | SIGMAR1 (0.48) | SIGMAR1MCHR1SLC6A12TMEM97POLB | |
| SCHEMBL5577342 | 0.86 | DRD4 (0.57) | SIGMAR1MCHR1CHRM4SLC6A12TMEM97 | |
| SCHEMBL5577906 | 0.86 | SIGMAR1 (0.48) | SIGMAR1MCHR1SLC6A12TMEM97POLB | |
| SCHEMBL5577726 | 0.86 | SIGMAR1 (0.51) | SIGMAR1MCHR1CHRM4SLC6A12TMEM97 | |
| SCHEMBL5577644 | 0.85 | CCR3 (0.53) | SIGMAR1CHRM4MEN1KMT2ADRD4 | |
| SCHEMBL5577659 | 0.84 | SIGMAR1 (0.52) | SIGMAR1MCHR1CHRM4SLC6A12TMEM97 | |
| SCHEMBL5577829 | 0.84 | SIGMAR1 (0.51) | SIGMAR1MCHR1SLC6A12TMEM97MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | SIGMAR1 3281/4885MCHR1 4381/4885CHRM4 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.